Journal
FRONTIERS IN ENDOCRINOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2022.1002916
Keywords
non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH); gut microbiota; metabolic diseases; adenosine monophosphate-activated protein kinase
Categories
Funding
- Postdoctoral Scientific Research Developmental Fund
- [LBH-Q20112]
Ask authors/readers for more resources
The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide, in parallel with the rise of metabolic diseases. NAFLD is closely related to metabolic syndrome and type 2 diabetes mellitus. Gut microbiota and functional molecules play important roles in the development and treatment of NAFLD.
There is a continuously rising incidence of non-alcoholic fatty liver disease (NAFLD) around the world, which parallels the increasing incidence of metabolic diseases. NAFLD is a range of liver conditions that contains simple non-alcoholic fatty liver and advanced non-alcoholic steatohepatitis. In serious cases, NAFLD may develop into cirrhosis or even liver cancer. NAFLD has an intense relationship with metabolic syndrome, type 2 diabetes mellitus. It is known that gut microbiota, and functional molecules such as adenosine monophosphate-activated protein kinase JNK, and peroxisome proliferator-activated receptors (PPARs) in progressing and treating NAFLD. Traditionally, the conventional and effective therapeutic strategy is lifestyle intervention. Nowadays, new medicines targeting specific molecules, such as farnesoid X receptor, PPARs, and GLP-1 receptor, have been discovered and shown beneficial effects on patients with NAFLD. In this article, we focus on the molecular mechanisms and therapeutic approaches to NAFLD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available